June 21, 2011
In the current study, the authors estimated hepatitis C virus incidence among HIV-infected men who have sex with men, 1990-2007, using data from 12 cohorts from the Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration. Estimates were based on standard incidence methods and methods for interval-censored data, taking into account that routine HCV data collection began in different calendar years in the cohorts.
Of 4,724 MSM with an HCV test included, 124 (4 percent) had only positive test results, 2,798 (93 percent) had only negative and 92 (3 percent) had both. HCV incidence in 1990 ranged from 0.9 to 2.2 per 1,000 person-years, depending on the analysis strategy. Incidence increased through 1995, when it ranged from an estimated 5.5 and 8.1 per 1,000 person-years. Substantial increases occurred from 2002 on, with incidence ranging between 16.8 and 30.0 per 1,000 person-years in 2005 and between 23.4 and 51.1 per 1,000 person-years in 2007.
"Our data support phylodynamic findings that HCV incidence had already increased among HIV-infected MSM from the mid-1990s," the authors concluded. "However, the main expansion of the HCV epidemic started after 2002. Incidence estimates obtained from cohort studies may help identify changes in the spread of important infections earlier and should guide routine testing policies to minimize further disease burden."
05.15.2011; Jannie Ja van der Helm and others; on behalf of the CASCADE Collaboration
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Long-Acting HIV Treatment: 5 Myths and Realities|
|Two-Drug HIV Treatment Regimens Effective in Latest Studies|
|The Need to Advocate for Fair HIV Drug Prices|
|'Stop Describing, Start Intervening': Can the CDC's New Viral Load Data Help Guide HIV Programs?|
|IL-1β Inhibitor Lowers Arterial Inflammation in Adults With Controlled HIV|
|Significant Interaction Between Once-Weekly Isoniazid/Rifapentine and Daily Dolutegravir: Study Stopped Due to Toxicity|